Restoring tumor-suppressive miRNAs (e.g., miR-26 and previously miR-150) or suppressing IL22/IL22RA disrupts this pathway, inhibits CTCL cell migration, and promotes apoptosis in vitro. The gene discussed is IL22; the disease is neoplasm.